Trial Profile
Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. A Multicenter, Single-arm Phase II Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2021
Price :
$35
*
At a glance
- Drugs Lurbinectedin (Primary)
- Indications Malignant-mesothelioma
- Focus Proof of concept; Therapeutic Use
- 13 Jul 2021 Status changed from active, no longer recruiting to completed.
- 16 Jan 2020 Results assessing lurbinectedin efficacy and safety data among pts with progressive Malignant Pleural Mesothelioma published in the Annals of Oncology
- 01 Oct 2019 Results presented in a Pharma Mar Media Release